Welcome to our dedicated page for CEL-SCI SEC filings (Ticker: CVM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Multikine trial read-outs, LEAPS patents and cash-runway projections make CEL-SCI鈥檚 disclosures some of the most technical in biotech. Finding Phase 3 timelines, FDA correspondence or insider purchases inside a 300-page 10-K can stall decision-making.
Stock Titan solves that problem. Our AI-powered engine turns every CEL-SCI annual report into a CEL-SCI annual report 10-K simplified summary, flags liquidity updates in each CEL-SCI quarterly earnings report 10-Q filing, and decodes CEL-SCI 8-K material events explained 鈥� like trial milestones or financing rounds 鈥� in plain English. Need real-time alerts? The platform streams CEL-SCI Form 4 insider transactions real-time so you can monitor CEL-SCI executive stock transactions Form 4 before market-moving announcements.
Every filing type is covered and searchable:
- 10-K & 10-Q: cash burn analysis, R&D spend, Multikine progress
- 8-K: rapid updates on trial data, regulatory news, or financing
- Form 4: CEL-SCI insider trading Form 4 transactions with AI context
- DEF 14A proxy: CEL-SCI proxy statement executive compensation tied to clinical milestones
Whether you鈥檙e comparing quarter-over-quarter R&D expenses, assessing dilution risk, or simply seeking CEL-SCI SEC filings explained simply, our platform delivers. Save hours with concise AI highlights, track filings the moment they hit EDGAR, and turn 鈥�understanding CEL-SCI SEC documents with AI鈥� from a goal into your daily workflow.
Cel鈥慡ci Corporation (CVM) reported unaudited results for the quarterly period ended June 30, 2025. Total assets were $20.34 million versus $26.99 million a year earlier, driven by a cash decline to $1.79 million from $4.74 million. The company recorded a nine鈥憁onth net loss of $19.31 million compared to $20.81 million in the prior year; research and development expense was $12.18 million and general and administrative expense was $6.59 million. Cash used in operating activities totaled $12.45 million while proceeds from issuance of common stock and pre鈥慺unded warrants were $12.56 million during the period. Management discloses substantial doubt about the company鈥檚 ability to continue as a going concern and estimates about $30 million will be required to finance the planned 212鈥憄atient confirmatory Multikine study. A 30鈥慺or鈥�1 reverse stock split became effective in May 2025 and shares outstanding were 5,321,341 at June 30, 2025. Subsequent to period end the company sold 1,500,000 shares for approximately $5.7 million.
CEL-SCI Corporation (NYSE American: CVM) has filed Amendment No. 1 to a Form S-3 shelf registration, enabling the company to issue up to $100 million of common stock, preferred stock (including convertibles), rights, warrants and/or units on a continuous basis. Pricing, size, and underwriter details will be set in future prospectus supplements.
The document retroactively reflects the 1-for-30 reverse stock split effected 20 May 2025, which cut outstanding shares from roughly 94 million to about 3.1 million while leaving authorised share counts unchanged. CEL-SCI lists 6,882,156 post-split shares outstanding as of 4 Aug 2025; the stock last closed at $9.25.
Net proceeds are earmarked primarily to advance lead immunotherapy 惭耻濒迟颈办颈苍别庐. In a Phase III trial鈥檚 target subgroup (no nodal involvement; low PD-L1) Multikine delivered 73 % 5-year survival versus 45 % for standard of care (hazard ratio 0.35). The FDA has cleared a 212-patient confirmatory registration study, potentially allowing an accelerated approval filing once fully enrolled.
CEL-SCI is a late-stage biotech with no product approvals or revenue. FY-2024 net loss was $27.6 million and the auditor flagged going-concern risk. Management warns that the contemplated securities are high-risk and potentially dilutive; proceeds are needed to fund trials, operations and working capital.
Cel-Sci Corp (CVM) Form 4: Senior Vice President John Cipriano received 7,500 stock options on 07/28/25 at an exercise price of $8.20, expiring 07/27/35. Vesting occurs in three equal annual tranches beginning one year from grant. No common shares were bought or sold; the filing records an 鈥淎鈥� code equity award rather than an open-market transaction. After the grant, Cipriano holds 38,008 derivative securities. The award is typical incentive compensation with negligible near-term cash flow or dilution impact for shareholders.
CEL-SCI Corp (CVM) 鈥� Form 4 insider transaction
Director Robert E. Watson bought 2,919 restricted shares of CEL-SCI on 25-Jul-2025 at $6.85 (prior day鈥檚 close), a cash outlay of roughly $20k. Following the purchase, Watson鈥檚 direct holdings increased to 3,733 shares. No derivative securities were involved and the filing shows the transaction was made directly with the company, suggesting an equity-based compensation or voluntary open-market style purchase rather than option exercise or planned sale. The filing does not reference any concurrent sales, options, or changes in indirect ownership.
The transaction is modest relative to CEL-SCI鈥檚 market capitalization and daily trading volume, but insider buying鈥攅specially by a board member鈥攃an signal personal confidence in the company鈥檚 prospects and may be viewed positively by investors monitoring governance alignment.
FAQ
What is the current stock price of CEL-SCI (CVM)?
What is the market cap of CEL-SCI (CVM)?
